by rvvadmin | Nov 3, 2021 | 2021
Building specialty psilocybin-based product pipeline Evaluating potential for neuropsychiatric indications for clinical studies in 2022 TORONTO, Nov. 03, 2021 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a...
by rvvadmin | Oct 26, 2021 | 2021
DSMB support in continuing the Phase 3 clinical trial; No serious adverse events and safety concerns reported to date. Phase 3 clinical trial to incorporate viral load testing for a minimum of 300 patients. Finalizing key research of thiol-based drugs, including...
by rvvadmin | Sep 21, 2021 | 2021
TORONTO, Sept. 21, 2021 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces...
by rvvadmin | Aug 17, 2021 | 2021
Novel discovery and research originated from Universidad Central del Caribe and St. Jude Children’s Research Hospital Medicinal mushroom compound with anticancer activities that have minimal effects on normal cells Showed superior potency against aggressive breast...
by rvvadmin | Aug 12, 2021 | 2021
TORONTO, Aug. 12, 2021 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (Frankfurt:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces...
